Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-01-25

FDA Approved: DULOXETINE — Supplemental Application (Aurobindo Pharma Limited)

View source ↗

Summary

The FDA approved a supplemental application for a generic duloxetine hydrochloride product from Aurobindo Pharma Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Duloxetine hydrochloride (duloxetine)

Snippet

SUPPL AP for DULOXETINE (DULOXETINE HYDROCHLORIDE)